Tevogen Bio (NASDAQ:TVGN) Posts Earnings Results, Beats Expectations By $1.01 EPS

Tevogen Bio (NASDAQ:TVGN) posted its quarterly earnings results on Friday. The company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.53) by $1.01, FiscalAI reports.

Tevogen Bio Price Performance

Tevogen Bio stock traded up $0.30 during midday trading on Friday, hitting $6.87. The company’s stock had a trading volume of 8,215 shares, compared to its average volume of 25,368. The company has a market cap of $28.99 million, a price-to-earnings ratio of -1.49 and a beta of 0.18. Tevogen Bio has a 1-year low of $3.64 and a 1-year high of $49.50. The company has a 50-day moving average price of $7.02 and a two-hundred day moving average price of $8.34.

Institutional Trading of Tevogen Bio

A number of institutional investors have recently modified their holdings of the stock. Deutsche Bank AG lifted its position in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares during the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a research note on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tevogen Bio has a consensus rating of “Reduce” and a consensus target price of $100.00.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.